66th ASH Annual Meeting: 655. Multiple Myeloma: Cellular Therapies: Poster II

Symposia: Multiple Myeloma: Cellular Therapies Oral and Poster Abstracts
Poster

Research, Combination therapy, Clinical trials, Adult, Translational Research, Elderly, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Clinical Research, Health outcomes research, Diseases, Patient-reported outcomes, Treatment Considerations, Biological therapies, Real-world evidence, Lymphoid Malignancies, Study Population, Human, Transplantation (Allogeneic and Autologous)

Halls G-H (San Diego Convention Center)

3382

Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis

Debashree Basudhar¹^*, Dante Descalzi-Montoya¹^*, Hao Tang¹^*, Minshi Wang¹^*, Fan Wu¹^*, P. Leif Bergsagel, MD², Xavier Leleu³, Daniela Hosseyni¹^*, Maria Chaudhry¹^*, Nathan Martin¹^* and Ethan G. Thompson, PhD¹^*

¹Bristol Myers Squibb, Princeton, NJ
²Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
³CHU La Milétrie, Poitiers, France

3383

Idecabtagene Vicleucel (ide-cel) Shows Similar Efficacy and Toxicity in Patients with Multiple Myeloma Aged 70 and Older Compared to Younger Patients: A Multicenter Cohort Study

Philipp Berning, MD¹^*, Markus Maulhardt²^*, Hristo Boyadzhiev^3,4^*, Anca Maria Albici⁵^*, Snjezana Janjetovic⁶^*, Anna Ossami Saidy⁷^*, Christian R Schultze-Florey, MD⁸^*, Simon Call¹^*, Natalie Schub⁹^*, Annamaria Brioli, MD, PhD⁸^*, Michael Daskalakis¹⁰^*, Juliane Knust, MD²^*, Justin Hasenkamp²^*, Matthias Stelljes, MD¹^*, Cyrus Khandanpour¹¹, Ulrike Bacher¹⁰^*, Christine Hanoun¹²^*, Florian Heidel, MD⁸, Hans Christian Reinhardt, MD¹², Georg Lenz¹, Gerald Wulf²^*, Friedrich Stölzel⁹^*, Bastian von Tresckow¹², Thomas Pabst³ and Evgenii Shumilov¹^*

¹Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
²Department of Hematology and Medical Oncology, University Hospital Goettingen, Goettingen, Germany
³Department of Medical Oncology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland
⁴Habichtswald Hospital, Kassel, Germany
⁵Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany
⁶Department of Hematology and Cell Therapy, Helios Klinikum Berlin-Buch, Berlin, Germany
⁷Department of Hematology and Cell Therapy, Helios Klinikum Berlin-Buch Berlin, Berlin, Germany
⁸Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
⁹Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein, Kiel, Germany
¹⁰Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
¹¹Department of Hematology and Oncology, University Hospital Schleswig-Holstein, University of Luebeck, Luebeck, Germany
¹²Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany

3384

Bird Regimen Followed By Anti-BCMA CAR T-Cell Immunotherapy As First-Line Therapy for Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Phase 3 Trial

Yue Zhou^1,2^*, Juan Chen^1,2^*, Qingya Cui^1,2^*, Haiping Dai^2,3^*, Zheng Li, MD^1,2^*, Jia Yin^1,2^*, Wei Cui^1,2^*, Mengyun Li^1,2^*, Xuekai Li^1,2^*, Xin Zhang^1,2^*, Feiran Gong^1,2^*, Xiaming Zhu^1,2^*, Liqing Kang⁴^*, Lei Yu⁴^*, Depei Wu, MD, PhD^5,6 and Xiaowen Tang^1,2^*

¹National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
²Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
³The first Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
⁴Shanghai Unicar-Therapy Bio-Medicine Technology Co.,Ltd, Shanghai, China
⁵Institute of Blood and Marrow Transplantation, Suzhou, China
⁶The First Affiliated Hospital of Soochow University, Suzhou, China

3385

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan¹^*, Chenxing DU²^*, Rui Lv³^*, Tengteng Yu⁴^*, Shuaishuai Zhang, MD⁴^*, Tingyu Wang⁵^*, Weiwei Sui, MD²^*, Shuhui Deng⁶^*, Yan Xu, MD⁷^*, Shuhua Yi, MD⁸^*, Dehui Zou⁹^*, Lu-Gui Qiu² and Gang An²^*

¹State Key Laboratory of Experimental Hematology, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood, TIANJIN, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin, CHN
⁴State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁵State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sci, Tian Jin, China
⁶State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Brookline, MA
⁷State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Boston, MA
⁸State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
⁹Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Scienfor Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

3386

CAC-MM-001: A B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Followed By Autologous Stem Cell Transplantation and Second CAR-T (CART-ASCT-CART2) in Newly Diagnosed Multiple Myeloma Patients with P53 Gene Abnormalities

Yuntong Liu¹^*, Weiwei Sui, MD²^*, Rui Lyu, MD³^*, Chenxing DU²^*, Shuaishuai Zhang, MD⁴^*, Tengteng Yu⁴^*, Jingyu Xu²^*, Wenqiang Yan⁵^*, Yuting Yan, MD⁴^*, Wei Liu²^*, Yi Wang²^*, Qi Wang, MD³^*, Yan Xu, MD⁶^*, Shuhua Yi⁷^*, Dehui Zou²^*, Lu-Gui Qiu² and Gang An²^*

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, UT, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
⁴State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
⁵State Key Laboratory of Experimental Hematology, State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood, TIANJIN, China
⁶State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Boston, MA
⁷National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

3387

Efficacy and Safety of BCMA-CAR-T Cell Therapy in Relapsed/Refractory Extramedullary Plasmacytoma: Exploring the Role of Consolidation Therapy

Lixia Ma¹^*, Rui Liu¹^*, Fan Yang¹^*, Yuelu Guo¹^*, Yimeng Dou¹^*, Biping Deng, BS, MD²^*, Zhonghua Fu¹^*, Xiaoyan Ke¹^* and Kai Hu, MD¹

¹Department of Lymphoma and Myeloma Research Center, Beijing Gobroad Hospital, Beijing, China
²Department of Cytology Laboratory, Beijing Gobroad Boren Hospital, Beijing, China

3388

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Barry Paul, MD, MS¹, Madhav V. Dhodapkar, MD PhD², Melissa Alsina, MD³^*, Jesús G. Berdeja, MD⁴, Shambavi Richard, MD⁵, Ravi Vij, MD, MBA⁶, Xavier Leleu⁷, Daniel N. Egan, MD⁸, P. Leif Bergsagel, MD⁹, Ran Reshef, MD, MSc¹⁰, Saad Z. Usmani, MD¹¹, Anna Truppel-Hartmann, MD¹²^*, Debashree Basudhar¹³^*, Ethan G. Thompson, PhD¹³^*, Fan Wu¹³^*, Laurie Eliason¹³^*, Soyun Park¹³^*, Sinhan Tran¹³^*, Maria Chaudhry¹³^*, David S. Siegel, MD, PhD¹⁴ and Krina K. Patel, MD, MSc¹⁵

¹Department of Hematologic Oncology and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC
²Winship Cancer Institute of Emory University, Atlanta, GA
³Moffitt Cancer Center, Tampa, FL
⁴Tennessee Oncology, Nashville, TN
⁵Mount Sinai Hospital, New York, NY
⁶Division of Oncology, Washington University School of Medicine, St. Louis, MO
⁷CHU La Milétrie, Poitiers, France
⁸Swedish Center for Blood Disorders and Stem Cell Transplants, Seattle, WA
⁹Mayo Clinic Arizona, Phoenix, AZ
¹⁰Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
¹¹Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
¹²2seventy bio, Cambridge, MA
¹³Bristol Myers Squibb, Princeton, NJ
¹⁴John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
¹⁵MD Anderson Cancer Center, University of Texas, Houston, TX

3389

A Phase 2 Study of CART-ASCT-CART2 Sandwich Regimen Treatment in Patients with Primary Plasma Cell Leukemia

Jingyu Xu¹^*, Shuaishuai Zhang, MD²^*, Wenqiang Yan³^*, Yuntong Liu⁴^*, Rui Lyu, MD⁵^*, Chenxing DU¹^*, Weiwei Sui, MD⁵^*, Lu-Gui Qiu, MD^6,7 and Gang An^6,8^*

¹State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
²State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
³State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, TIANJIN, CHN
⁴State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, UT, China
⁵State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Colleg, Tianjin, China
⁶State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology&Blood Diseases Hospital, Chinese Academy of Medical Sciences&Peking Union Medical College, Tianjin, China
⁷Institute of Multiple Myeloma, Beijing GoBroad Boren Hospital, BEIJING, China
⁸Institute of Multiple Myeloma, Beijing GoBroad Boren Hospital, Beijing, China

3390

Updated Comparative Efficacy of Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 2–4 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison

Nieves Lopez-Muñoz¹^*, Noffar Bar, MD², Joris Diels³^*, Suzy van Sanden³^*, João Mendes⁴^*, Seina Lee⁴^*, Teresa Hernando⁵^*, Nikoletta Lendvai⁶^*, Nitin Patel⁷^*, Tadao Ishida⁸, Jeremy Er⁹, Simon J Harrison, MBBS, PhD¹⁰ and Urvi A. Shah, MD¹¹

¹Hospital Universitario 12 de Octubre, Madrid, Spain
²Department of Internal Medicine, Section of Hematology, Yale University School of Medicine and Yale Cancer Center, New Haven, CT
³Janssen Pharmaceutica NV, Beerse, Belgium
⁴Janssen Global Services, LLC, Raritan, NJ
⁵Janssen-Cilag, Madrid, Spain
⁶Oncology Clinical Development, Johnson and Johnson Innovative Medicine, Bridgewater, NJ
⁷Legend Biotech USA Inc., Somerset, NJ
⁸Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
⁹Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
¹⁰Clinical Haematology and Centre of Excellence for Cellular Immunotherapy, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia
¹¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH